natgillin/translations-raw huggingface dataset:
ponovno poudarja, da je cilj Nekdanje jugoslovanske republike Makedonije in vseh držav zahodnega Balkana – nedvoumno članstvo v EU – skladen s solunsko agendo; meni, da je treba možnosti pristopa k EU spoštovati, da bi se utrdila stabilnost in mir v tej regiji;
Reiterates the goal of clear European membership for the Former Yugoslav Republic of Macedonia as well as for all Western Balkan countries, in line with the Thessaloniki Agenda; believes that the prospect of EU accession has to be respected in order to consolidate stability and peace in the region;
meni, da je treba izboljšati sistem vzgoje in izobraževanja, vlaganje v človeški kapital ter dostop prebivalstva do interneta, da bi odgovorili na potrebe družbe;
Considers that the education and training system, investment in human capital and the population's access to the internet must be improved in order to respond to the needs of society;
naroči svojemu predsedniku, naj to resolucijo posreduje Svetu, Komisiji, vladam in parlamentom držav članic, vladi in parlamentu Nekdanje jugoslovanske republike Makedonije ter generalnemu sekretarju Združenih narodov.
Instructs its President to forward this resolution to the Council and the Commission, the governments and parliaments of the Member States, the government and parliament of the Former Yugoslav Republic of Macedonia and the other candidate countries, and the UN Secretary-General.
ob upoštevanju svoje resolucije z dne 20. junija 2007 o razvojnih ciljih tisočletja – vmesna točka Sprejeta besedila, P6_TA(2007)0274 .
having regard to its resolutions of 20 June 2007 on the Millennium Development Goals – the midway point Texts Adopted, P6_TA(2007)0274 .
, o sporazumih o gospodarskem partnerstvu z dne 23. maja 2007 Sprejeta besedila, P6_TA(2007)0204 .
, of 23 May 2007 on Economic Partnership Agreements Texts Adopted, P6_TA(2007)0204 .
in o aidsu z dne 30. novembra 2006 Sprejeta besedila, P6_TA(2006)0526 .
, and of 30 November 2006 on AIDS Texts Adopted, P6_TA(2006)0526 .
ob upoštevanju predloga Sklepa Sveta o sprejetju Protokola o spremembi Sporazuma o trgovinskih vidikih pravic intelektualne lastnine (TRIPS), sestavljenega 6. decembra 2005 v Ženevi, v imenu Evropske skupnosti ( KOM(2006)0175 ),
having regard to the proposal for a Council decision accepting, on behalf of the European Community, of the Protocol amending the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), done at Geneva on 6 December 2005 ( COM(2006)0175 ),
ob upoštevanju Uredbe (ES) št. 816/2006 Evropskega parlamenta in Sveta z dne 17. maja 2006 o prisilnih licencah za patente, povezane s proizvodnjo farmacevtskih izdelkov za izvoz v države s težavami v javnem zdravju UL L 157, 9.6.2006, str.
having regard to Regulation (EC) No 816/2006 of the European Parliament and of the Council of 17 May 2006 on compulsory licensing of patents relating to the manufacture of pharmaceutical products for export to countries with public health problems OJ L 157, 9.6.2006, p.
ob upoštevanju Sporazuma o trgovinskih vidikih pravic intelektualne lastnine ("Sporazum TRIPS"), sprejetega 15. aprila 1994 v Marakešu,
having regard to the Agreement on Trade-Related Aspects of Intellectual Property Rights ("TRIPS Agreement") adopted in Marrakesh on 15 April 1994,
ob upoštevanju deklaracije iz Dohe o Sporazumu TRIPS in javnem zdravju, ki jo je ministrska konferenca Svetovne trgovinske organizacije (STO) sprejela 14. novembra 2001 ("deklaracija iz Dohe") WT/MIN(01)/DEC/W/2, 14. november 2001.
having regard to the Doha Declaration on the TRIPS Agreement and Public Health adopted on 14 November 2001 by the Ministerial Conference of the World Trade Organization (WTO) ("Doha Declaration") WT/MIN(01)/DEC/W/2, 14 November 2001.
ob upoštevanju sklepa generalnega sveta STO z dne 30. avgusta 2003 ("sklep STO"), sprejetega v skladu z odstavkom 6 deklaracije iz Dohe o Sporazumu TRIPS in javnem zdravju,
having regard to the Decision of the WTO General Council of 30 August 2003 ("WTO Decision") adopted pursuant to Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health,
ob upoštevanju Protokola o spremembi Sporazuma o trgovinskih vidikih pravic intelektualne lastnine (TRIPS), sestavljenega dne 6. decembra 2005 v Ženevi ("Protokol"),
having regard to the Protocol amending the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), done at Geneva on 6 December 2005 ("Protocol",
ker več kot 95 % od 39,5 milijona ljudi na svetu, ki trpi za HIV/aidsom, živi v državah v razvoju, večinoma v Afriki; ker se ocenjuje, da je na svetu zaradi te bolezni 15 milijonov sirot, od teh jih 12,3 milijona živi v podsaharski Afriki,
whereas over 95% of the 39.5 million people in the world suffering from HIV/AIDS live in developing countries, mostly in Africa; whereas there are an estimated 15 million HIV/AIDS orphans globally, 12.3 million of them living in Sub-Saharan Africa,
ker je pred začetkom veljave Sporazuma TRIPS leta 1994 zmožnost držav v razvoju s srednje visokim prihodkom za proizvodnjo poceni generičnih zdravil narasla in so tudi zelo revne države začele postajati zmožne pridobivati nekatera poceni generična zdravila na svetovnem trgu, ne glede na to, ali so bili ti proizvodi zaščiteni s patentom ali ne,
whereas before the entry into force in 1994 of the TRIPS Agreement, the ability of some middle-income developing countries to produce low-cost generic medicines increased, and even very poor States started to become able to obtain certain low-cost generic medicines on the world market, regardless of whether such products were still patent-protected or not,
ker je deklaracija iz Dohe ponovno potrdila tako imenovane prožnosti, vgrajene v Sporazum TRIPS, ter jih še razširila z vzpostavitvijo pravnih mehanizmov, s katerimi države, ki nimajo zmogljivosti za proizvodnjo generičnih nadomestkov za draga patentirana zdravila v okviru doma izdanih prisilnih licenc, uvažajo zdravila iz držav, ki so jim zmožne in pripravljene pomagati, brez vmešavanja teh imetnikov patentov,
whereas the Doha Declaration reconfirmed the so-called flexibilities built into the TRIPS Agreement and amplified them further by establishing legal machinery to enable countries lacking the capacity to manufacture generic substitutes for costly patented medicines under domestically issued compulsory licences to obtain imports from countries able and willing to assist them without interference from the relevant patent holders,
ker bi ta rešitev, ki je na začetku imela obliko opustitve, znane kot sklep STO, postala stalna v obliki protokola k Sporazumu TRIPS, o katerega sprejetju trenutno razpravlja Parlament,
whereas this solution, initially embodied in a waiver known as the WTO Decision, could be rendered permanent in the form of a Protocol to the TRIPS Agreement whose acceptance is currently under consideration by Parliament,
ker člen 30 Sporazuma TRIPS članicam dovoljuje, da lahko določijo omejene izjeme pri izključnih pravicah, ki jih vsebuje patent, če take izjeme niso v nerazumnem nasprotju z običajnim izkoriščanjem patenta in nerazumno ne ogrožajo legitimnih interesov lastnika patenta ob upoštevanju legitimnih interesov tretjih strank; ker če država, ki daje pomoč, izvaža potrebna zdravila v državo uvoznico, to ne sme pomembno vplivati na lokalni trg države izvoznice,
whereas Article 30 of the TRIPS Agreement allows members to "provide limited exceptions to the exclusive rights conferred by a patent, provided that such exceptions do not unreasonably conflict with a normal exploitation of the patent and do not unreasonably prejudice the legitimate interests of the patent owner, taking account of the legitimate interests of third parties"; whereas, because the assisting country would export needed medicines to the importing country, there should be no significant economic impact on the local market of the exporting country,
ker doslej še nobena država ni uradno obvestila Sveta za Sporazum TRIPS, da namerava uporabiti mehanizem, vzpostavljen na podlagi sklepa STO o uvozu cenejših zdravil,
whereas no country has so far made an official notification to the Council for TRIPS of its intention to use the mechanism created by the WTO Decision to import cheaper medicines,
ker postopkovne in vsebinske zahteve, ki veljajo za izdajo prisilnih licenc s strani držav uvoznic (če je to potrebno) in izvoznic, kot tudi pogojev in obvestil, povezanih z izdajanjem dovoljenj, predstavljajo najpomembnejše potencialne ovire za učinkovito uporabo sklepa STO,
whereas the procedural and substantive requirements that govern the issuance of compulsory licences by importing (where applicable) and exporting countries, as well as the conditions and notifications connected with that licensing, constitute the principal potential obstacles to the effective use of the WTO Decision,
ker so države članice že prenesle sklep STO v nacionalno pravo in zato odlaganje sprejetja protokola na čas po 1. decembru 2007 ne bi ustvarilo pravne praznine,
whereas the Member States have already transposed the WTO Decision into internal law, and consequently delaying acceptance of the Protocol until after 1 December 2007 would not create a legal vacuum,
ker bi morala Evropska unija izrecno podpreti polno izvajanje prožnosti iz Sporazuma TRIPS v državah v razvoju, ki jih priznava deklaracija iz Dohe, zaradi spodbujanja dostopa do zdravil za vse,
whereas the EU should expressly endorse full implementation in the developing countries of the flexibilities in the TRIPS Agreement as recognized in the Doha Declaration "to promote access to medicines for all",
ker namerava EU s pogajanji o sporazumih o gospodarskem partnerstvu in drugimi dvostranskimi ali regionalnimi prostotrgovinskimi sporazumi uvesti nove obveznosti glede intelektualne lastnine STO plus za države AKP in druge revne države v razvoju ter najmanj razvite države, vključno z upoštevanjem ali sprejetjem obveznosti pogodbe o sodelovanju na področju patentov in pogodbe o patentnem pravu ter z vključitvijo pogojev iz Direktive 2004/48/ES Evropskega parlamenta in Sveta z dne 29. aprila 2004 o uveljavljanju pravic intelektualne lastnine UL L 157, 30.4.2004, str.
whereas through the Economic Partnership Agreement (EPA) negotiations and other bilateral or regional Free Trade Agreements (FTAs), the EU proposes to impose new intellectual property "WTO+" obligations on the countries of Africa, the Caribbean and the Pacific (ACP) and other poor developing countries and the least developed countries (LDCs), including adherence to or acceptance of the obligations of the Patent Cooperation Treaty (PCT) and the Patent Law Treaty (PLT), and the incorporation of the terms of Directive 2004/48/EC of the European Parliament and the Council of 29 April 2004 on the enforcement of intellectual property rights OJ L 157, 30.4.2004, p.
; ker EU tudi postavlja pogoje glede načina, kako strani določijo svoj režim izčrpanja pravic,
; whereas the EU also sets conditions on the way in which parties can determine their regime of exhaustion,
poudarja, da je dostop do farmacevtskih izdelkov po sprejemljivih cenah v revnih državah v razvoju in najmanj razvitih državah bistvenega pomena za doseganje predlaganih razvojnih ciljev Evropske unije in bi prispeval k zmanjšanju revščine, povečanju varnosti ljudi ter spodbujal človekove pravice in trajnostni razvoj,
S tresses that access to affordable pharmaceutical products in poor developing countries and LDCs is essential to attain the proposed EU development goals and would contribute to poverty reduction, increase human security, and promote human rights and sustainable development;
meni, da bi si morala politika EU prizadevati za čim večjo dostopnost farmacevtskih proizvodov po sprejemljivih cenah v državah v razvoju,
Believes that EU policy should aim at maximizing the availability of pharmaceutical products at affordable prices in the developing world;
poziva Svet, naj prizna, da mora EU nujno sprejeti dodatne ukrepe za spodbujanje prenosa tehnologije, raziskav, krepitve zmogljivosti, regijskih oskrbovalnih sistemov in pomoči pri registraciji, da se olajša in poveča proizvodnja farmacevtskih izdelkov v samih državah v razvoju,
Calls on the Council to recognise that the EU must take additional measures as a matter of urgency with a view to encouraging the transfer of technology, research, capacity strengthening, regional supply systems and help with registration, in order to facilitate and increase the production of pharmaceutical products by the developing countries themselves;
poziva Komisijo in države članice, da zagotovijo konkretno finančno pomoč za prenos farmacevtske tehnologije v države v razvoju in razvijanje njihovih zmogljivosti na tem področju, kot tudi za lokalno proizvodnjo farmacevtskih izdelkov v vseh državah v razvoju, zlasti v najmanj razvitih državah, pri izpolnjevanju obveznosti iz člena 66(2) Sporazuma TRIPS,
Asks the Commission and the Member States to provide concrete financial support for pharmaceutical-related transfer of technology and capacity-building for developing countries and local production of pharmaceuticals in all developing countries, especially LDCs, in discharging the obligations established by Article 66.2 of the TRIPS Agreement;
poziva Svet, da sprejme obvezo o določeni ravni financiranja za posodobitev ali izgradnjo zmogljivosti za proizvodnjo farmacevtskih izdelkov v lasti lokalnih oseb v državah v razvoju (vključno z najmanj razvitimi) ter poveča skupno financiranje javno-zasebnega partnerstva pri izvajanju raziskav in razvoju zdravil posebnega pomena za države v razvoju,
Asks the Council to commit to a specified level of funding to upgrade or construct pharmaceutical production facilities owned by local persons in developing countries (including LDCs), and increase the EU's aggregate funding to Public-Private Partnerships pursuing research and development of medicines of special relevance to developing countries;
poziva Komisijo, naj v različnih okvirih zagotovi finančna sredstva za raziskave in razvoj na področju bolezni, povezanih z revščino, tropskih bolezni in zapostavljenih bolezni, vključno z javno-zasebnimi partnerstvi in drugimi načini financiranja, obenem pa naj podpira raziskovalne ustanove, ki so pripravljene sodelovati v okviru pobud na področju javnega zdravja, ki si prizadevajo za te cilje,
Asks the Commission to grant funding for research and development on poverty-related, tropical and neglected diseases across a broad spectrum of locations, including Public-Private Partnerships and other possible funding ventures, and to support research institutes willing to cooperate with public health initiatives dedicated to these efforts;
poziva Svet, naj podpre mnenje, da mehanizem, vzpostavljen s sklepom STO in Protokolom k Sporazumu TRIPS, le delno rešuje problem dostopa do zdravil in javnega zdravja in da so drugi ukrepi za izboljšanje zdravstvenega varstva in infrastrukture prav tako potrebni,
Asks the Council to support the idea that the mechanism created by the WTO Decision and the Protocol to the TRIPS Agreement represents just a part of the solution to the problem of access to medicines and public health and that other measures to improve health care and infrastructure are equally indispensable;
poziva Svet, naj podpira revne države v razvoju, ki uporabljajo tako imenovane prožnosti, vgrajene v Sporazum TRIPS in priznane v okviru deklaracije iz Dohe, da bodo v okviru domačih programov javnega zdravja sposobne zagotoviti nujna zdravila po dostopnih cenah,
Asks the Council to support the developing countries which use the so-called flexibilities built into the TRIPS Agreement and recognized by the Doha Declaration in order to be able to provide essential medicines at affordable prices under their domestic public health programmes;
spodbuja države v razvoju, naj uporabijo vsa sredstva, ki jih imajo na razpolago v okviru Sporazuma TRIPS, na primer prisilne licence in mehanizem iz člena 30,
Encourages the developing countries to use all means available to them under the TRIPS Agreement, such as compulsory licences and the mechanism provided by Article 30 thereof;
poziva Svet, naj skupaj s Parlamentom sprejme skupno politično izjavo, da države članice lahko v skladu z domačim patentnim pravom še naprej uporabljajo vse določbe o izvzetju, ki jih vsebuje Sporazum TRIPS, za dovoljevanje proizvodnje in izvoza z namenom reševanja potreb javnega zdravja in držav uvoznic ter poziva Svet, naj Komisijo pooblasti, da se vzdrži sprejemanja ukrepov, ki bi posegali v te postopke,
Calls on the Council to adopt a Joint Policy Statement with Parliament to the effect that the Member States remain free to use all exceptions from the TRIPS Agreement under their domestic patent laws to authorise production and export "to address public health needs in importing Members" and asks the Council to ensure that the Commission refrains from taking action to interfere with these proceedings;
poziva Svet, naj izpolnjuje svoje obveznosti iz deklaracije iz Dohe in omeji mandat Komisije ter ji s tem prepreči, da bi se v okviru pogajanj o gospodarskem partnerstvu z državami AKP in drugih prihodnjih dvostranskih in regionalnih sporazumov z državami v razvoju dogovarjala glede določb TRIPS plus o farmacevtskih proizvodih, ki vplivajo na javno zdravje in na dostop do zdravil, na primer glede določb o ekskluzivnosti podatkov, podaljšanju patentov in omejitve razlogov za izdajo prisilnih licenc,
Calls on the Council to meet its commitments to the Doha Declaration and to restrict the Commission's mandate so as to prevent it from negotiating pharmaceutical-related TRIPS-plus provisions affecting public health and access to medicines, such as data exclusivity, patent extensions and limitation of grounds of compulsory licences, within the framework of the EPA negotiations with the ACP countries and other future bilateral and regional agreements with developing countries;
poziva Komisijo, naj podpre zahtevo, da prijavitelji patentov razkrijejo vir in izvor izuma, ki izhaja iz bioloških virov in je povezan s tradicionalnim znanjem držav v razvoju, da bi se spodbujala pravična delitev koristi in tehnologije, ki izhajata iz teh virov, z državami dobaviteljicami,
Asks the Commission to support disclosure by patent applicants of the source and origin of inventions deriving from biological resources and associated traditional knowledge found in developing countries with a view to promoting the equitable sharing of the benefits and technology derived from those resources by supplying countries;
poziva Komisijo, naj podpira "strategije združevanja javnih naročil" iz člena 31(b) Sporazuma TRIPS ter druge strategije, ki jih lahko uporabijo države ali skupine držav za povečanje kupne moči in uresničevanje ekonomije obsega pri proizvodnji generičnih zdravil po dostopni ceni ter za spodbujanje neposrednih vlaganj v lokalne proizvodne zmogljivosti v določeni regiji,
Calls on the Commission to support "pool procurement strategies" under Article 31(b) of the TRIPS Agreement and other strategies which could be used by countries or groups of countries to provide greater buying power and economies of scale in the production of generic medicines at affordable prices and stimulate direct investment in local production facilities within a region;
poziva Svet, naj Komisijo pooblasti, da bo dejavno podpirala delo medvladne delovne skupine za javno zdravje, inovacije in intelektualno lastnino pri Svetovni zdravstveni organizaciji in da redno poroča Evropskemu parlamentu o njenem delu,
Asks the Council to mandate the Commission to proactively support the work of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (IGWG) at the World Health Organization and to report regularly to the European Parliament on its work;
poziva najmanj razvite države in druge revne države, naj s sprejetjem ukrepov preprečijo preusmerjanje zdravil, zajetih v prisilnih licencah, iz države, s čimer bi zagotovile, da zdravila prejme pomoči potrebno lokalno prebivalstvo,
Calls on LDCs and other poor countries to take the necessary measures to prevent medicines covered by compulsory licensing from leaving the country and ensuring that the medicines go to the local population in need;
ker je Parlament začel proces demokratičnega nadzora pri izvajanju Uredbe (ES) št. 1905/2006 Evropskega parlamenta in Sveta z dne 18. decembra 2006 o vzpostavitvi instrumenta za financiranje razvojnega sodelovanja UL L 378, 27.12.2006, str.
whereas Parliament has launched a process of democratic scrutiny of the implementation of Regulation (EC) No 1905/2006 of the European Parliament and of the Council of 18 December 2006 establishing a financing instrument for development cooperation OJ L 378, 27.12.2006, p.
ker je v skladu s členom 2(1) DCI najpomembnejši cilj sodelovanja na podlagi tega instrumenta izkoreninjenje revščine v partnerskih državah, vključno z izpolnjevanjem razvojnih ciljev tisočletja (RCT),
whereas, according to Article 2(1) of the DCI, the overarching objective of cooperation under that instrument shall be "the eradication of poverty in partner countries", including "pursuit of the Millennium Development Goals"(MDGs),
na podlagi člena 81 svojega Poslovnika, v katerih je Komisijo opozoril, da je po njegovem mnenju v številnih osnutkih sklepov o pripravi strateških dokumentov prekoračila svoja izvedbena pooblastila
pursuant to Rule 81 of its Rules of Procedure, signalling to the Commission that in Parliament's view it had exceeded its implementing powers in a number of draft Commission decisions establishing strategy papers,
CMT-2007-1709, priloga pa je vodena kot dokument komitologije št.
CMT-2007-1709 - annex registered as comitology document no.
, v katerem so bila poudarjena glavna horizontalna vprašanja Parlamenta, na več kot 150 straneh pa je tudi povzetek ocene Parlamenta o posameznih strateških dokumentih, Komisija pa je bila naprošena, naj zagotovi specifične informacije o posameznih primerih,
, highlighting Parliament's main horizontal concerns and with more than 150 pages summarising Parliament's assessment of the individual strategy papers and requesting the Commission to supply specific information on individual cases,
ker komisarja trdita, da RCT ni mogoče doseči, če je pozornost usmerjena le na osnovne storitve, obenem pa ponovno potrjujeta svojo zavezanost cilju, da se v skladu z državnimi programi DCI doseže pomoč v višini 20 %, ki naj bi se do leta 2009 dodelila za osnovno in srednješolsko izobraževanje ter osnovne zdravstvene storitve,
whereas the Commissioners state that the MDGs cannot be achieved by a focus on basic services alone, at the same time reaffirming their commitment to achieving the objective of 20% of assistance under DCI country programmes being allocated by 2009 to basic and secondary education and basic health,
ker Komisija sporoča, da preučuje, kako izboljšati postopek posvetovanja z različnimi zainteresiranimi stranmi, in poudarja, da bodo pri pripravi letnih akcijskih načrtov po potrebi opravili presojo vpliva predlaganih ukrepov z vidika spola,
whereas the Commission states that it is considering how to improve the process of consultation with the different stakeholders and points out that in the drawing up of the annual action programmes a gender impact assessment will be made of the measures proposed when relevant,
ker je treba horizontalna vprašanja – spodbujanje človekovih pravic, enakost med spoloma, demokracijo, dobro upravljanje, otrokove pravice, pravice invalidov in domorodnih ljudstev, okoljsko trajnost in boj proti virusu HIV/aidsu – vključiti v vse programe,
whereas mainstreaming of cross-cutting issues – promotion of human rights, gender equality, democracy, good governance, the rights of the child, of disabled people and of indigenous people, environmental sustainability and combating HIV/AIDS – must be undertaken in all programmes,